However, since recent studies have suggested that the immunotherapeutic effect of anti-CTLA-4 antibodies are independent of checkpoint blockade,29 CTLA-4-targeting cancer immunotherapy does not necessarily increase the risk of autoimmune diseases as it does not have to inactivate physiological function of CTLA-4. The gene discussed is CTLA4; the disease is autoimmune disease.